Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 1874 • 2016 ACR/ARHP Annual Meeting
Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests
Louise Parker¹, Kevin Howell², Voon H. Ong³ and Christopher P.Denton⁴, ¹Centre for Rheumatology and Connective Diseases, UCL Medical School and Royal Free Hosp, London, United Kingdom, ²Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom, ³Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Raynaud’s phenomenon is common but can progress to definite connective tissue disease. We have observed long term follow up of an unselected consecutive…
Abstract Number: 2889 • 2016 ACR/ARHP Annual Meeting
Therapeutic Plasma Exchange for the Treatment of Raynaud’s and Digital Ulcers in Systemic Sclerosis: A Systematic Review
Edward S Harris¹, Herbert J Meiselman², Patrick M Moriarty³ and Allan Metzger⁴, ¹Scleroderma Education Project Ltd, Madison, WI, ²Keck School of Medicine, University of Southern California, Los Angeles, CA, ³Clinical Pharmacology, University of Kansas Medical Center, Kansas City, KS, ⁴RDL Reference Laboratory Inc, Los Angeles, CA
Background/Purpose: Raynaud's phenomenon (RP) is an early marker of microvascular damage in systemic sclerosis (SSc) and digital ulcers (DU) are a serious complication of vascular…
Abstract Number: 2909 • 2016 ACR/ARHP Annual Meeting
Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis
John Pauling^1,2, Tracy M. Frech^3,4, Michael Hughes⁵, Jessica K. Gordon⁶, Robyn T. Domsic⁷, Francesca Ingegnoli⁸, Neil J. McHugh^1,9, Sindhu R. Johnson¹⁰, Marie Hudson¹¹, Francesco Boin¹², Voon Ong¹³, Marco Matucci Cerinic¹⁴, Nezam Altorok¹⁵, Marina Scolnik¹⁶, Mandana Nikpour¹⁷, Ankoor Shah¹⁸, Janet E. Pope¹⁹, Dinesh Khanna²⁰ and Ariane L. Herrick²¹, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ⁴Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁵Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine - Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁸Department of Rheumatology, Istituto Gaetano Pini, University of Milano, Italy, Milano, Italy, ⁹Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom, ¹⁰Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹¹Department of Medicine, McGill University and Jewish General Hospital, Montreal, QC, Canada, ¹²Rheumatology, University California San Francisco, San Francisco, CA, ¹³Rheumatology, University College London Medical School, Royal Free Hospital, London, UK, London, United Kingdom, ¹⁴Department of Medicine, Division of Rheumatology, University of Florence, Italy, Florence, Italy, ¹⁵Rheumatology, University of Toledo Medical Center,, Toledo, OH, ¹⁶Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁷Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Australia, ¹⁸Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ¹⁹Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ²⁰Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ²¹Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: The Raynaud’s Condition Score (RCS) diary is a clinician-derived validated patient-reported outcome (PRO) instrument for assessing the frequency, duration and severity of Raynaud's phenomenon…
Abstract Number: 164 • 2016 ACR/ARHP Annual Meeting
99mtc-Hdp Digital Blood Flow Scintigraphy for Assessment of Raynaud Phenomenon Associated with Hand-Arm Vibration Syndrome
Kyung-Ann Lee¹, Hyun-Woo Jeong², Sang Heon Lee³ and Hae-Rim Kim⁴, ¹Devision of rheumatology, Department of internal medicine, Konkuk University Medical center, Seoul, Korea, The Republic of, ²Department of Nuclear medicine, Konkuk University Medical center, Seoul, Korea, The Republic of, ³Department of Internal Medicine,Division of Rheumatology., Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁴Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea, The Republic of
Background/Purpose: This study aimed to analyze the 99mTc-HDP scintigraphic features in hand-arm vibration syndrome (HAVS) and to compare with primary Raynaud’s phenomenon (RP) and secondary…
Abstract Number: 842 • 2016 ACR/ARHP Annual Meeting
Aminaphtone Treatment Increases Skin Blood Perfusion and Related Clinical Symptoms in Patients Affected By Raynaud’s Phenomenon: A Pilot Study Based on Laser Speckle Contrast Analysis
Barbara Ruaro, Sabrina Paolino, Carmen Pizzorni, Maurizio Cutolo and Alberto Sulli, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy
Background/Purpose: Aminaphtone is an oral vasoactive drug used to treat microvascular impairement since 30 years, and recently suggested to down-regulate endothelin-1 production by endothelial cells,…
Abstract Number: 823 • 2015 ACR/ARHP Annual Meeting
Anti-IFI16 Antibodies in Scleroderma Are Associated with Digital Gangrene
Zsuzsanna McMahan¹, Ami A. Shah², Dhananjay Vaidya³, Fredrick M. Wigley⁴, Antony Rosen⁵ and Livia Casciola-Rosen⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine, School of Medicine, Johns Hopkins, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Mason Lord Bldg Ctr Tower, Johns Hopkins University, School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Our aim was to examine and confirm the association between anti-IFI16 antibodies and clinical features of scleroderma. Methods: Sera from a discovery sample…
Abstract Number: 848 • 2015 ACR/ARHP Annual Meeting
Nitroglycerin Patch Application in Systemic Sclerosis: Evaluation By Laser Doppler Imaging
Georgiana Bentea, Aurelien Wauters, Jean-Claude Wautrecht and Elie Cogan, Erasme Hospital, Brussels, Belgium
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease, commonly associated with Raynaud phenomenon (RP). The aim of this study was to characterize the microvascular…
Abstract Number: 1880 • 2015 ACR/ARHP Annual Meeting
Circulating Microparticle Populations May Differentiate Between Connective Tissue Diseases.
Eoghan M. McCarthy^1,2, Daniel Moreno-Martinez³, Fiona Wilkinson⁴, Neil J McHugh^5,6, Ian N. Bruce^7,8, Yvonne Alexander³, John D. Pauling^6,9 and Ben Parker^7,8, ¹The University of Manchester, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, Mmanchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Rheumatology, Bath Institute of Rheumatic Diseases, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁶Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁷Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁸Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁹Upper Borough Walls, Royal National Hospital for Rheumatic Disease, Bath, United Kingdom
Background/Purpose: Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). Circulating MPs levels are altered…
Abstract Number: 1894 • 2015 ACR/ARHP Annual Meeting
Calcium Channel Blockers Are More Effective in the Treatment of Primary Raynaud’s Phenomenon Compared to Secondary: A Meta-Analyis
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Peter Tugwell⁶, Jordi Pardo⁷, Elizabeth Ghogomu⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of calcium channel blockers (CCBs) versus placebo for the treatment of Raynaud's phenomenon (RP) comparing primary to secondary…
Abstract Number: 1896 • 2015 ACR/ARHP Annual Meeting
Early Signs, Symptoms and Auto-Antibodies to Predict Diffuse Cutaneous or Limited Cutaneous Systemic Sclerosis at First Presentation
WMT van den Hombergh¹, HKA Knaapen-Hans¹, Patricia E. Carreira^2,3, FHJ van den Hoogen¹, Jaap Fransen¹ and MC Vonk¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³Rheumatology Unit, Hospital 12 de Octubre, Hospital 12 de Octubre, Madrid, Spain
ABSTRACT Background/Purpose: Diffuse cutaneous systemic sclerosis (dcSSc) is associated with a poorer prognosis compared to limited cutaneous SSc (lcSSc), due to earlier and more severe…
Abstract Number: 1928 • 2015 ACR/ARHP Annual Meeting
Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis
Shadia Nada¹, Farouk Abu Alhana², Yongqing Wang², Nezam Altorok³ and Bashar Kahaleh⁴, ¹Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, ²The University of Toledo, Toledo, OH, ³Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, ⁴Medicine/Rheumatology, The University of Toledo, Toledo, OH
Background/Purpose: Nearly all patients with Systemic sclerosis (SSc) suffer from vascular dysfunction as illustrated by the uniform presence of Raynaud’s phenomena. The role of vascular…
Abstract Number: 2256 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics, Laboratory Findings and Nailfold Capillaroscopy Microscopy Patterns in a Monocentric Series of 123 Patients with Idiopathic Pernio
Thi Phuong Uyen Doan¹, Sara Hussein¹, Martial Koenig² and France Joyal¹, ¹Université de Montréal, Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Few studies have looked at the characteristics of patients diagnosed with pernio and the significance of the use of capillaroscopy in these patients. The…
Abstract Number: 2379 • 2015 ACR/ARHP Annual Meeting
Clinical Follow-up Predictors of Disease Pattern Change in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International and Retrospective Study
Franco Franceschini¹, Elena Bartoloni-Bocci², Santos Castañeda³, Laura Nuno⁴, Carlo Alberto Scirè⁵, Francisco Javier López-Longo⁶, Julia Martínez-Barrio⁷, Ilaria Cavazzana¹, Paolo Airò⁸, Javier Bachiller Corral⁹, Alberto Sifuentes Giraldo¹⁰, Rossella Neri¹¹, Simone Barsotti¹², Roberto Caporali¹³, Carlomaurizio Montecucco¹⁴, Marcello Govoni¹⁵, Renato La Corte¹⁵, Federica Furini¹⁵, Florenzo Iannone¹⁶, Margherita Giannini¹⁷, Enrico Fusaro¹⁸, Simone Parisi¹⁹, Giuseppe Paolazzi²⁰, Giovanni Barausse²¹, Raffaele Pellerito²², Alessandra Russo²², Lesley Ann Saketkoo²³, Norberto Ortego-Centeno²⁴, Luca Quartuccio²⁵, Christof Specker²⁶, Andreas Schwarting²⁷, Kostantinos Triantafyllias²⁸, Carlo Selmi²⁹, Fausto Salaffi³⁰, Marco Amedeo Cimmino³¹, Annamaria Iuliano³², Fabrizio Conti³³, Gianluigi Baiocchi³⁴, Elena Bravi³⁵, Anna Ghirardello³⁶, Trinitario Pina³⁷, Miguel A. Gonzalez-Gay³⁸, Lorenzo Cavagna³⁹ and AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹²Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹³University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁴Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ¹⁵UOC Reumatologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy, ¹⁶Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ¹⁷DIM, Rheumatology Unit, Bari, Italy, ¹⁸Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy, ¹⁹Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy, ²⁰Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ²¹Rheumatology, Ospedale di Trento, Trento, Italy, ²²Division of Rheumatology, Mauriziano Hospital, Turin, Italy, ²³New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Tulane University Lung Center, New Orleans, LA, ²⁴Hospital San Cecilio. Granada, Granada, Spain, ²⁵S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²⁶Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany, ²⁷Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁸ACURA Rheumatology Center, Bad Kreuznach, Germany, ²⁹Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ³⁰Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ³¹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, ³²Osp. San Camillo, Roma, Italy, ³³Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ³⁴Rheumatology Unit, Department of Internal Medicine, S.Maria Hospital –IRCCS, Reggio Emilia, Italy, ³⁵Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ³⁶Department of Medicine-DIMED, University of Padova, Padova, Italy, ³⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³⁸Reumatologia, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ³⁹Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) constitute the classic clinical triad of antisynthetase syndrome (ASSD). Even if reported in up to 90% of…
Abstract Number: 2909 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus
Jennifer Medlin¹, Karen E. Hansen², Sara Fitz³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Rheumatology/Medicine, Univ of Wisconsin, Madison, WI, ³Department of Dermatology, Mercy Medical Center, Dubuque, IA, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is commonly diagnosed in females of reproductive age, with those diagnosed after the age of 50 referred to as…
Abstract Number: 2963 • 2015 ACR/ARHP Annual Meeting
Correlations Between Microvasculature Changes and Angiogenic Factors in Systemic Sclerosis – Data from a Single Center Registry
Radim Becvar¹, Simona Skacelova², Jiri Stork³, Hana Hulejová⁴, Ivana Putova⁵, Michal Tomcik⁶ and Marie Jachymova⁷, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Clinic of Dermatology and Venerology, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology of the 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ⁷Second Internal Clinic – Clinic of Cardiology and Angiology, General University Hospital,, Prague, Czech Republic
Background/Purpose: Histopathological hallmarks of systemic sclerosis (SSc) are perivascular infiltrates and a reduced capillary density, which precede the excessive accumulation of extracellular matrix components in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].